Trevogrumab
What it is & what research shows
Reference overviewTrevogrumab is an investigational antibody against myostatin, also called GDF8. It is being studied as a way to preserve lean tissue during semaglutide-associated weight loss. The phase 2 COURAGE program compares combinations involving semaglutide and trevogrumab, with or without the separate activin-A antibody garetosmab. Sponsor conference results report better lean-mass preservation. [1.1][1.2]
Results from a two-drug regimen must be distinguished from the three-drug regimen. DXA body composition does not directly measure muscle quality or strength, and the findings do not validate products sold online as myostatin inhibitors. A source-linked study result with a verified dose and schedule is not yet available in this overview. This is a gap in this page, not a claim that no research exists. [2.1][2.2]
Sources & reading scope
- [1.1] COURAGE: semaglutide with trevogrumab, with or without garetosmabTrial registration · Study design and any posted results; registration does not establish treatment benefit.
- [1.2] COURAGE: complete 26-week resultsSponsor report · Conference results on DXA lean and fat mass; not proof of strength gains.
- [2.1] COURAGE: semaglutide with trevogrumab, with or without garetosmabTrial registration · Study design and any posted results; registration does not establish treatment benefit.
- [2.2] COURAGE: complete 26-week resultsSponsor report · Conference results on DXA lean and fat mass; not proof of strength gains.
Study-summary coverage
No completed study summaries are linked to this compound page yet. This is a coverage gap on PED Evidence, not evidence that human studies or other research do not exist.
Filter, save and compare Trevogrumab studies →Studies & trial records
Original papers, trial registrations and sponsor disclosures are labeled separately. Multiple links may describe the same study.
More about Trevogrumab: identity, safety & reference details
Also known as REGN1033
Start with the research
An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.
Open studies and trial records- Uses & research
The phase 2 COURAGE program compares combinations involving semaglutide and trevogrumab, with or without the separate activin-A antibody garetosmab. Sponsor conference results report better lean-mass preservation. [1][2]
- Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Safety & evidence boundaries
Results from a two-drug regimen must be distinguished from the three-drug regimen. DXA body composition does not directly measure muscle quality or strength, and the findings do not validate products sold online as myostatin inhibitors.
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Identity, names & formulations
Canonical compound: Trevogrumab · trevogrumab
Searchable names: REGN1033
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Sources for this profile
- 1. COURAGE: semaglutide with trevogrumab, with or without garetosmab Trial registration · Study design and any posted results; registration does not establish treatment benefit.
- 2. COURAGE: complete 26-week results Sponsor report · Conference results on DXA lean and fat mass; not proof of strength gains.
Reference facts checked 2026-09-24. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.
Study model describes the source. Confidence depends on methods, replication, population and outcome.
Loading compound research…